Charged Phosphinate Linkers for Antibody Conjugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The use of cell-binding molecule-drug conjugates in cancer therapy is limited by the formation of protein aggregates due to hydrophobic linkers, which complicates the scale-up process and decreases yield, especially when high drug loading is desired, as it leads to nonspecific toxicity and immunogenicity.
Innovation Solution
The development of charged phosphinate linkers that minimize aggregation by enabling higher drug loading while maintaining affinity, allowing for the conjugation of drugs to cell-binding agents like antibodies, and facilitating retention within target cells, even in multidrug-resistant cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If hydrophobic linkers are used for conjugation, then drug loading can be achieved, but protein aggregation occurs which complicates scale-up and decreases yield
Solution Approach 1:
The patent changes the chemical parameter of the linker from hydrophobic to hydrophilic (charged phosphinate group). This parameter change fundamentally alters the linker's interaction with water and protein surfaces, preventing hydrophobic aggregation while maintaining drug conjugation capability. The charged phosphinate linker achieves high drug loading (DCR up to 20) without the aggregation problems that plague hydrophobic linkers, thereby resolving the contradiction between drug loading quantity and conjugate yield.
2Quantity of substance
If higher drug loading is desired, then potency increases, but nonspecific toxicity and immunogenicity occur
Solution Approach 1:
The charged phosphinate linker acts as an intermediary between the antibody and the cytotoxic drug. This intermediary maintains proper spacing and orientation, ensuring that the drug is delivered specifically to target cells via the antibody's specificity. The charged nature of the linker prevents nonspecific interactions with off-target proteins, thereby enabling high drug-to-antibody ratios without increasing nonspecific toxicity.
3Ease of manufacture
If hydrophobic linkers are used, then conjugation can be achieved, but aggregation complicates the scale-up process
Solution Approach 1:
The invention extracts the hydrophobic character from the linker structure and replaces it with a hydrophilic charged phosphinate group. This extraction of the problematic hydrophobic property eliminates the aggregation tendency that complicates scale-up, while retaining the essential conjugation functionality. The result is a simplified manufacturing process that does not require complex aggregation management steps.
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
Cell binding agent-drug conjugates comprising phosphinate-based charged linkers and methods of using such linkers and conjugates are provided.